Comparison of Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Coronary Heart Dis-ease
10.6039/j.issn.1001-0408.2016.12.09
- VernacularTitle:瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较
- Author:
Like ZHANG
;
Yu CHEN
- Publication Type:Journal Article
- Keywords:
Rosuvastatin;
Atorvastatin;
Coronary heart disease;
Efficacy;
Safety
- From:
China Pharmacy
2016;27(12):1611-1613
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the efficacy and safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease. METHODS:96 patients with coronary heart disease were randomly divided into observation group and control group. All patients received reasonable diet control,low molecular weight heparin,Aspirin enteric-coated tablet,β-blockers,nitric acid lipids and other conventional treatment,but no vitamins and other antioxidant drugs. Based on it,observation group was orally given 10 mg Rosuvastatin tablet,once a day;control group was given 20 mg Atorvastatin capsule,once a day. The treatment course for both groups was 6 months. Clinical efficacy, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol(HDL-C),high-sensitivity C-reactive protein(hs-CRP)and left ventricular ejection fraction (LVEF) before and after treatment,and the incidence of adverse reactions in 2 groups were observed. RESULTS:There were no significant differences in the total effective rate and incidence of adverse reactions between 2 groups(P>0.05). Before treat-ment,there were no significant differences in the TC,TG,LDL-C,HDL-C,hs-CRP and LVEF between 2 groups(P>0.05). After treatment,TC,TG,LDL-C,HDL-C and hs-CRP in 2 groups were significantly lower than before,and TC,LDL-C and hs-CRP in observation group were lower than control group,HDL-C and LVEF in 2 groups were significantly higher than before,and observa-tion group was higher than control group,the differences were statistically significant (P<0.05). CONCLUSIONS:Rosuvastatin and atorvastatin has similar efficacy and safety in the treatment of coronary heart disease,but rosuvastatin is superior to atorvastatin in terms of reducing lipid levels.
